Bicalutamide ('Casodex') 150mg in addition to standard care in patients with nonmetastatic prostate cancer: Updated results from a randomised double-blind phase III study (median follow-up 5.1y) in the early prostate cancer programme

Wirth M. ; Tyrrell C. ; Delaere K. ; Sanchez-Chapado M. ; Ramon J. ; Wallace D.M.A. ; Hetherington J. ; Pina F. ; Heyns C. ; Borchers T. ; Morris T. ; Armstrong J. (2005)


Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'+) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b -4, any N, M0 prostate cancer. In Trial 24, at 5.1y median follow-up, the addition of bicalutamide significantly (P<0.0001) improved objective progression-free survival (PFS) and prostate-specific antigen PFS compared with standard care alone. There was no significant difference in overall survival (P = 0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer. © 2005 Nature Publishing Group. All rights reserved.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: